The settlement allows Pfizer to continue selling its own drug, Inflectra, in the U.S., Pfizer said in a statement provided to Bloomberg Law Thursday. The drugmaker didn’t reveal the terms of the deal.
The case, filed in 2017, is one of several antitrust lawsuits over biosimilars—less expensive versions of complex biologic drugs, which are made using living cells.
Pfizer alleged that J&J violated antitrust laws by threatening to withhold rebates from United ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.